NCT01050062已完成不适用
Post Marketing Surveillance on Long Drug Use of Micombi Combination Tablets in Patients With Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,452
- 试验地点
- 314
- 主要终点
- Incidence of Adverse Events (AEs)
研究概览
简要总结
The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Micombi® Combination Tablet AP
干预措施: Telmisartan 40mg (Drug)
Micombi® Combination Tablet AP
干预措施: Hydrochlorothiazide 12.5mg (Drug)
Micombi® Combination Tablet BP
干预措施: Telmisartan 80mg (Drug)
Micombi® Combination Tablet BP
干预措施: Hydrochlorothiazide 12.5mg (Drug)
结局指标
主要结局
Incidence of Adverse Events (AEs)
时间窗: Week 52
The number of patient with any AEs, patients with drug-related AEs
次要结局
- Diastolic Blood Pressure (DBP)(Week 0 and Week 52)
- Systolic Blood Pressure (SBP)(Week 0 and Week 52)
- Target Blood Pressure Achievement Rate(Week 52)
- Blood Pressure Normalised Rate(Week 52)
研究者
研究点 (314)
Loading locations...
相似试验
已完成
不适用
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in JapanHypercholesterolemiaFamilial HypercholesterolemiaNCT02808403Amgen6,000
已完成
不适用
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)HypertensionNCT02262611Boehringer Ingelheim266
已完成
不适用
Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)Noonan SyndromeGenetic DisorderNCT03435627Novo Nordisk A/S71
已完成
不适用
Post-marketing Surveillance for Hypertensive Patients With Diabetes and/or Chronic Kidney DiseaseHypertensionNCT01363336Bayer1,882
已完成
不适用
Lyrica (Pregabalin) Korean Post Marketing Surveillance StudyNeuropathic PainPost-market SurveillanceEpilepsyFibromyalgiaNCT01220180Pfizer's Upjohn has merged with Mylan to form Viatris Inc.4,175